Actively Recruiting
Nephroprotective Effect of Nicorandil in Type 2 Diabetes Mellitus
Led by Tanta University · Updated on 2024-05-28
46
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the possible nephroprotective effect of nicorandil in patients with type 2 diabetes mellitus .
CONDITIONS
Official Title
Nephroprotective Effect of Nicorandil in Type 2 Diabetes Mellitus
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients newly diagnosed with type 2 diabetes mellitus controlled with diet and good glycemic index (Hb A1C < 7)
- Age between 18 and 60 years old
- Both sexes
- Stage 1 and Stage 2 chronic kidney disease according to KDIGO
- Controlled hypertension
You will not qualify if you...
- Pregnant and lactating females
- Patients with hypersensitivity to nicorandil
- Other causes of chronic kidney disease or nephropathy such as uncontrolled hypertension, renal malignancy, collagen diseases like amyloidosis, and autoimmune diseases such as SLE and rheumatic fever
- Uncontrolled hypertension and its antihypertensive medications (ACE inhibitors, ARBs, and others)
- Patients receiving nephrotoxic drugs such as aminoglycosides, non-steroidal anti-inflammatory drugs, and contrast media
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tanta University
Tanta, EL Gharbia, Egypt
Actively Recruiting
Research Team
M
Mohammed A El-hazzab
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here